145 related articles for article (PubMed ID: 11813463)
1. Ziprasidone hydrochloride.
Am J Health Syst Pharm; 2002 Jan; 59(1):28-9. PubMed ID: 11813463
[No Abstract] [Full Text] [Related]
2. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
[TBL] [Abstract][Full Text] [Related]
3. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
[TBL] [Abstract][Full Text] [Related]
4. Methodological concerns in a trial of ziprasidone and olanzapine.
Ross DE
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
[No Abstract] [Full Text] [Related]
5. Methodological concerns in a trial of ziprasidone and olanzapine.
Carnahan RM; Perry PJ
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
[No Abstract] [Full Text] [Related]
6. Parkinsonism with intramuscular ziprasidone.
Bilal L; Tsai C; Gasper JJ; Ndlela JC
Am J Psychiatry; 2005 Dec; 162(12):2392-3. PubMed ID: 16330610
[No Abstract] [Full Text] [Related]
7. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
8. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
Scahill L; Blair J; Leckman JF; Martin A
J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
[No Abstract] [Full Text] [Related]
9. Ziprasidone approved.
Hirsch M
Harv Ment Health Lett; 2001 Jun; 17(12):8. PubMed ID: 11439926
[No Abstract] [Full Text] [Related]
10. Mania associated with initiation of ziprasidone.
Nolan BP; Schulte JJ
J Clin Psychiatry; 2003 Mar; 64(3):336. PubMed ID: 12716277
[No Abstract] [Full Text] [Related]
11. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
12. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
13. Possible ziprasidone-induced mania.
Larson MF; Hauser A
J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1012; discussion 1012-3. PubMed ID: 12964565
[No Abstract] [Full Text] [Related]
14. Prolonged erections associated with ziprasidone treatment: a case report.
Reeves RR; Kimble R
J Clin Psychiatry; 2003 Jan; 64(1):97-8. PubMed ID: 12590634
[No Abstract] [Full Text] [Related]
15. Methodological issues in a comparative study of ziprasidone and risperidone.
Gharabawi GM; Bossie CA; Mahmoud R; Canuso CM; Lasser RA; Turkoz I; Greenspan A
J Clin Psychiatry; 2006 Jan; 67(1):162-3; author reply 163-4. PubMed ID: 16426103
[No Abstract] [Full Text] [Related]
16. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
17. Ziprasidone, a new atypical antipsychotic drug.
Carnahan RM; Lund BC; Perry PJ
Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184
[TBL] [Abstract][Full Text] [Related]
18. A case report with ziprasidone-induced catatonic symptoms.
Markham-Abedi C; McNeely C; de Leon J
J Neuropsychiatry Clin Neurosci; 2007; 19(4):476-7. PubMed ID: 18070860
[No Abstract] [Full Text] [Related]
19. Ziprasidone augmentation of clozapine in 11 patients.
Kaye NS
J Clin Psychiatry; 2003 Feb; 64(2):215-6. PubMed ID: 12633133
[No Abstract] [Full Text] [Related]
20. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
